Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/96490
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHardingham, J.en
dc.contributor.authorGrover, P.en
dc.contributor.authorWinter, M.en
dc.contributor.authorHewett, P.en
dc.contributor.authorPrice, T.en
dc.contributor.authorThierry, B.en
dc.date.issued2015en
dc.identifier.citationMolecular Medicine, 2015; 21(Suppl 1):S25-S31en
dc.identifier.issn1528-3658en
dc.identifier.issn1528-3658en
dc.identifier.urihttp://hdl.handle.net/2440/96490-
dc.description.abstractCirculating tumor cells (CTC) may be defined as tumor- or metastasis-derived cells that are present in the bloodstream. The CTC pool in colorectal cancer (CRC) patients may include not only epithelial tumor cells, but also tumor cells undergoing epithelial–mesenchymal transition (EMT) and tumor stem cells. A significant number of patients diagnosed with early stage CRC subsequently relapse with recurrent or metastatic disease despite undergoing “curative” resection of their primary tumor. This suggests that an occult metastatic disease process was already underway, with viable tumor cells being shed from the primary tumor site, at least some of which have proliferative and metastatic potential and the ability to survive in the bloodstream. Such tumor cells are considered to be responsible for disease relapse in these patients. Their detection in peripheral blood at the time of diagnosis or after resection of the primary tumor may identify those early-stage patients who are at risk of developing recurrent or metastatic disease and who would benefit from adjuvant therapy. CTC may also be a useful adjunct to radiological assessment of tumor response to therapy. Over the last 20 years many approaches have been developed for the isolation and characterization of CTC. However, none of these methods can be considered the gold standard for detection of the entire pool of CTC. Recently our group has developed novel unbiased inertial microfluidics to enrich for CTC, followed by identification of CTC by imaging flow cytometry. Here, we provide a review of progress on CTC detection and clinical significance over the last 20 years.en
dc.description.statementofresponsibilityJennifer E Hardingham, Phulwinder Grover, Marnie Winter, Peter J Hewett, Timothy J Price, and Benjamin Thierryen
dc.language.isoenen
dc.publisherFeinstein Institute for Medical Researchen
dc.rights© The authoren
dc.subjectEpithelial Cells; Humans; Colorectal Neoplasms; Recurrence; Granulocyte Colony-Stimulating Factor; Receptors, G-Protein-Coupled; Prognosis; Cell Separation; Microfluidics; Gene Expression; History, 20th Century; History, 21st Century; Basic Helix-Loop-Helix Transcription Factors; Neoplastic Stem Cells; Neoplastic Cells, Circulating; Epithelial-Mesenchymal Transition; Biomarkersen
dc.titleDetection and clinical significance of circulating tumor cells in colorectal cancer - 20 years of progressen
dc.typeJournal articleen
dc.identifier.rmid0030038401en
dc.identifier.doi10.2119/molmed.2015.00149en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1045841en
dc.identifier.pubid219265-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS05en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidHardingham, J. [0000-0001-8277-1199]en
dc.identifier.orcidPrice, T. [0000-0002-3922-2693]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.